Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Acute promyelocytic leukemia incidence in Andean highlanders with the NFKB1 haplotype (rs230511)

Ricardo Amaru, Victor Gordeuk, Julieta Luna et al. Nov 03, 2025 pp. 6931-6931 10.1182/blood-2025-6931

Abstract Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), characterized by the oncogenic fusion pro...

Bispecific antibodies in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

Natalie Boytsov, Jasjit Multani, Molly Purser et al. Nov 03, 2025 pp. 2790-2790 10.1182/blood-2025-2790

Abstract Introduction: Bispecific antibodies (BsAbs) including teclistamab (tec), talquetamab (talq), and elranatamab (elra) have emerged as...

粪便微生物移植在治疗类固醇难治性胃肠道移植物抗宿主病中的应用

Xiaotian Yang, Ziyi Hao, Yan Wan et al. Nov 03, 2025 pp. 7776-7776 10.1182/blood-2025-7776

Abstract Objective To assess the efficacy and safety of fecal microbiota transplantation (FMT) in the treatment of gastrointestinal graft-ve...

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Gregorio Barila, Francesco Tarantini, Alfonso Piciocchi et al. Nov 03, 2025 pp. 6363-6363 10.1182/blood-2025-6363

Abstract Despite the improvement in the treatment of multiple myeloma (MM) patients, there is still a consistent fraction of patients who ha...

Real-world impact of lipophilic statins on survival outcomes in polycythemia vera and essential thrombocythemia

Tenzin Tamdin, Zhang Jingyao, Sadkishya Bhandari Nov 03, 2025 pp. 7318-7318 10.1182/blood-2025-7318

Abstract Background: Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms frequently associate...

Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission

Calvin Le, Xueyan Chen, Shunya Kodaira et al. Nov 03, 2025 pp. 3519-3519 10.1182/blood-2025-3519

Abstract Introduction : MFC-based MRD testing is now routinely used in AML, but methodological refinements are needed to optimize assay perfo...

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

David Swoboda, Amy DeZern, James England et al. Nov 03, 2025 pp. 4349-4349 10.1182/blood-2025-4349

Abstract Background Recent advances in Artificial Intelligence (AI), particularly in Large Language Models (LLMs) like GPT-4o (ChatGPT) and...

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Romain Guieze, Emmanuelle Ferrant, Fatiha Merabet et al. Nov 03, 2025 pp. 684-684 10.1182/blood-2025-684

Abstract Background Continuous therapy with covalent BTK inhibitors (BTKi) has become a cornerstone strategy for patients with chronic lymph...

Gut microbiota-mediated tryptophan metabolism plays dual-effects in diffuse large B-cell lymphoma via regulating 3-IAA/5-HTP balance and antitumor immunity

Na He, Can Can, Daoxin Ma Nov 03, 2025 pp. 3262-3262 10.1182/blood-2025-3262

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL), the most common aggressive lymphoma, exhibits limited immunotherapeutic respons...

The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis

Manjola Balliu, Valentina Boldrini, Chiara Maccari et al. Nov 03, 2025 pp. 5529-5529 10.1182/blood-2025-5529

Abstract BACKGROUND. Following demonstration of abnormally activated JAK2/STAT signalling caused by driver mutations in JAK2, CALR, MPL, JAK...

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Mary Katherine Anderson, Valerie Shostrom, Robert Bociek et al. Nov 03, 2025 pp. 8021-8021 10.1182/blood-2025-8021

Abstract Introduction: Autologous hematopoietic stem cell transplantation (ASCT) has curative potential for relapsed dif...

Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort

Yuan Yao, Tait Shanafelt, Sameer Parikh et al. Nov 03, 2025 pp. 128-128 10.1182/blood-2025-128

Abstract Background: Monoclonal B-cell lymphocytosis (MBL), a precursor to chronic lymphocytic leukemia (CLL), is an understudied yet common...

iPSC-derived epstein-barr virus-specific T cells with dual alpha T cell receptors

Kosuke Matsuzaki, Midori Ishii, Shintaro Kinoshita et al. Nov 03, 2025 pp. 7653-7653 10.1182/blood-2025-7653

Abstract T cells play a critical role in immune defense by eliminating virus-infected and malignant cells. Their antigen specificity is dete...

Consolidation of adult inpatient sickle cell care to improve patients' and learners' experiences: A qualitative exploration of various stakeholders' perspectives

Max Jordan Nguemeni Tiako, Ethan Manelin, Maureen Okam Achebe Nov 03, 2025 pp. 2593-2593 10.1182/blood-2025-2593

Abstract Background: SCD patients are often scrutinized by healthcare providers during acute illness: their pain is often doubted, and they...

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Yuhua Ru, Jacques-Emmanuel Galimard, Depei Wu et al. Nov 03, 2025 pp. 6080-6080 10.1182/blood-2025-6080

Abstract Introduction While the tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes for Philadelphia chromosome-positive B...

Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison

Lay She Ng, Alice He, Yone Phar Lin et al. Nov 03, 2025 pp. 7419-7419 10.1182/blood-2025-7419

Abstract Background: Bruton's tyrosine kinase inhibitors (BTKis), like acalabrutinib and zanubrutinib, have revolutioniz...

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour et al. Nov 03, 2025 pp. 3583-3583 10.1182/blood-2025-3583

Abstract Introduction: BGB-16673 is an orally available protein degrader that blocks BTK signaling by tagging BTK for degradation through the...

Impact of slim-CRAB criteria on diagnostic practices among patients with MGUS in the veteran health administration

Mengmeng Ji, Mahta Salehi, Mei Wang et al. Nov 03, 2025 pp. 3972-3972 10.1182/blood-2025-3972

Abstract Introduction In 2014, the International Myeloma Working Group (IMWG) modified the diagnostic criteria for active multiple myeloma (M...

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Monica Carpenedo, Catherine Broome, Blanca Sánchez González et al. Nov 03, 2025 pp. 6245-6245 10.1182/blood-2025-6245

Abstract Introduction Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder resulting in thrombocytopenia, bleeding, cons...

External validation of the istopmm prediction model in a US population

Marisa Sobczak, Jacqueline Lozano, Henrique Guimaraes Barbosa Coelho et al. Nov 03, 2025 pp. 2195-2195 10.1182/blood-2025-2195

Abstract Background: The iStopMM Prediction Model was developed to predict the probability of ≥10% bone marrow plasma cells (BMPC) in patien...

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Julia-Annabell Georgi, Martin Krusche, Franziska Dlouhy et al. Nov 03, 2025 pp. 4968-4968 10.1182/blood-2025-4968

Abstract Background VEXAS syndrome (vacuoles, E1 enzyme, x-linked, autoinflammatory, somatic) is an acquired hematoinflammatory disorder cau...

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Cameron Hunter, Karthik Chetlapalli, Satoko Ito et al. Nov 03, 2025 pp. 6208-6208 10.1182/blood-2025-6208

Abstract Introduction: Patients with newly diagnosed acute myeloid leukemia (ndAML) often undergo frontline intensive ch...

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Maria Julia Montoro, Pamela Acha, Claudia Haferlach et al. Nov 03, 2025 pp. 2068-2068 10.1182/blood-2025-2068

Abstract Background & aim: Myelodysplastic syndromes with isolated deletion of chromosome 5q (MDS-del(5q)) are associated with low-risk...

Standard tyrosine kinase inhibitor dose versus dose de-escalation prior to treatment-free remission attempt in chronic myeloid leukemia: A single-center 25-year retrospective study

Mark Pusung, Christopher Eide, Nicola Long et al. Nov 03, 2025 pp. 2011-2011 10.1182/blood-2025-2011

Abstract Background As frontline treatment for CML, tyrosine kinase inhibitors (TKIs) have significantly improved patient prognosis and can...

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Hira Mian, Muhammad Salman Faisal, Tiening Chen et al. Nov 03, 2025 pp. 133-133 10.1182/blood-2025-133

Abstract Background: Ciltacabtagene Autoleucel (Cilta-cel), an anti-BCMA CAR-T cell therapy, is approved for relapsed/refractory multiple my...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page